| Ytd | 87.43% | |
| 1y | 81.34% |
| Open | 10.69 | Prev Close | 10.58 | Low | 10.52 | High | 10.74 | Mkt Cap | 775.93M |
| Vol | 800.79K | Avg Vol | 1.83M | EPS | -0.98 | P/E | -10.81 | Forward P/E | -9.48 |
| Beta | -0.87 | Short Ratio | 7.72 | Inst. Own | 22.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 9.41 | 200-d Avg | 6.66 | 1yr Est | 19.00 |
CADL News
Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncolog
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
NEEDHAM, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Candel Therapeutics NASDAQ: CADL Chief Executive Officer Dr. Paul Peter Tak said the company remains
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagen
NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (
NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (
NEEDHAM, Mass. , May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
